100
Participants
Start Date
July 27, 2020
Primary Completion Date
December 30, 2021
Study Completion Date
December 30, 2021
EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide). The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations spaced 21-28 days apart.
Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)
The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (43 volunteers)
"Federal State Budgetary Institution of Healthcare Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency (FGBUZ MSCH-163, FMBA of Russia)", Kol'tsovo
"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology Vector"
OTHER_GOV